AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Pluri Inc.

Director's Dealing Jan 8, 2021

6990_rns_2021-01-07_fbf553c4-e56e-4094-acaa-48a0f4d85572.pdf

Director's Dealing

Open in Viewer

Opens in native device viewer

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP or Section 30(h) of the Investment Company Act of 1940

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response 0.5

1. Name and Address of Reporting Person*
Levi, Rami Avraham
2. Issuer Name and Ticker or Trading Symbol
PLURISTEM THERAPEUTICS INC [ PSTI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X
Director
10% Owner
(Last)
(First)
(Middle)
MATAM PARK, BUILDING #5
3. Date of Earliest Transaction (Month/Day/Year)
01/05/2021
Officer (give title
below)
Other (specify below)
(Street) 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)
HAIFA L3 3508409 X Form filed by One Reporting Person
(City) (State) (Zip) Form filed by More than One Reporting Person
Table I – Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction
2A. Deemed
Date
Execution Date, if
(Month/Day/Year)
any
(Month/Day/Year)
3.
Transaction
Code (Instr.
8)
4. Securities Acquired (A) or Disposed Of
(D) (Instr. 3, 4 and 5)
5. Amount of Securities
Beneficially Owned
Following Reported
Transaction(s) (Instr. 3
6. Ownership
Form: Direct (D) or
Indirect (I) (Instr. 4)
7. Nature of
Indirect
Beneficial
Ownership
Code V Amount (A) or
(D)
Price and 4) (Instr. 4)
Restricted Stock Units(1) 01/05/2021(2) A 20,000 A \$0 20,000 D
Table II – Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
3)
2.
Conversion
or Exercise
Price of
Derivative
Security
3. Transaction
Date
(Month/Day/Year)
3A. Deemed
Execution Date, if
any
(Month/Day/Year)
4.
Transaction
Code (Instr.
8)
and 5)
5. Number of
Derivative
Securities
Acquired (A) or
Disposed of (D)
(Instr. 3, 4
6. Date Exercisable
and Expiration Date
(Month/Day/Year)
7. Title and Amount of Securities
Underlying Derivative Security
(Instr. 3 and 4)
8. Price of
Derivative
Security
(Instr. 5)
9. Number of
Derivative
Securities
Beneficially
Owned
Following
Reported
10.
Ownership
Form:
Direct (D)
or Indirect
(I) (Instr.
4)
11. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Code V (A) (D) Date
Exercisable
Expiration
Date
Title Amount or
Number of
Shares
Transaction(s)
(Instr. 4)

Explanation of Responses:

  1. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

  2. The shares vest over four years as follows: 12.5% shall vest on the 6 month anniversary of the date of grant and the remaining shares vest in 14 equal instalments every 3 months thereafter. Remarks:

/s/ Rami Avraham Levi 01/07/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Talk to a Data Expert

Have a question? We'll get back to you promptly.